In a report released on January 5, Thomas Shrader from BTIG maintained a Buy rating on Gain Therapeutics (GANX – Research Report), with a price target of $10.00. The company’s shares closed last Friday at $3.75.
According to TipRanks, Shrader is a 4-star analyst with an average return of 5.1% and a 40.30% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Aldeyra Therapeutics, Alector, and Acumen Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Gain Therapeutics with a $8.75 average price target, representing a 133.33% upside. In a report released on January 2, Maxim Group also maintained a Buy rating on the stock with a $10.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $6.19 and a one-year low of $2.00. Currently, Gain Therapeutics has an average volume of 80.25K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Gain Therapeutics (GANX) Company Description:
Gain Therapeutics Inc is a development-stage biotechnology company developing novel therapeutics to treat diseases caused by protein misfolding, with an initial focus on lysosomal storage disorders (LSDs), including rare genetic diseases and neurological disorders. Its pipeline includes the GLB1 gene, GBA1 gene, IDUA gene, and GALC gene.
Read More on GANX:
- Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024
- Gain Therapeutics files to sell 744,026 shares of common stock for holders
- Gain Therapeutics price target lowered to $9 from $10 at H.C. Wainwright
- Gain Therapeutics announces preclinical data on class of allosteric regulators
- Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment Option
